MedPath

Gadoxetic acid

Generic Name
Gadoxetic acid
Brand Names
Eovist, Primovist
Drug Type
Small Molecule
Chemical Formula
C23H30GdN3O11
CAS Number
135326-11-3
Unique Ingredient Identifier
3QJA87N40S
Background

Gadoxetic acid (gadoxetate) is a paramagnetic gadolinium-containing contrast agent in which its salt form, gadoxetate disodium, is used for intravenous injection. Ethoxybenzyl diethylenetriaminepentaacetic acid is the moiety that chelates with a gadolinium ion and forms a stable complex with it to make up the drug. It is marketed by Bayer HealthCare Pharmaceuticals and FDA approved on July 3, 2008.

Indication

Gadoxetate is used as a contrast medium for magnetic resonance imaging (MRI) to detect and characterize lesions in the liver.

Associated Conditions
Chronic Liver Diseases (CLD)
Associated Therapies
-
Clinical Trials
Related News

Improving CBCT for Liver IG-SBRT Using Gadoxetate Disodium

Phase 4
Withdrawn
Conditions
Primary Liver Cancer
Metastatic Liver Cancer
Interventions
Drug: Primovist
First Posted Date
2017-07-12
Last Posted Date
2021-01-27
Lead Sponsor
Slawa Cwajna
Registration Number
NCT03215355
Locations
🇨🇦

Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada

Evaluation of Transient Dyspnea During Gadoxetic Acid Enhanced Multiphasic Liver MRI

Completed
Conditions
Dyspnea
Interventions
Drug: gadoxetic acid
Other: Magnetic resonance imaging (MRI)
First Posted Date
2015-03-24
Last Posted Date
2021-05-26
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
60
Registration Number
NCT02395991
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

24hr Imaging Of HCC After EOVIST

Early Phase 1
Withdrawn
Conditions
Hepatocellular Carcinoma
Interventions
Drug: Eovist
First Posted Date
2013-10-24
Last Posted Date
2015-09-23
Lead Sponsor
Massachusetts General Hospital
Registration Number
NCT01968629
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
Drug: Eovist
First Posted Date
2013-06-04
Last Posted Date
2020-07-08
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
24
Registration Number
NCT01867424
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis

Phase 4
Completed
Conditions
Hepatocellular Carcinoma
Interventions
Drug: GADOXETIC ACID
First Posted Date
2012-04-11
Last Posted Date
2016-08-23
Lead Sponsor
Sara Varea
Target Recruit Count
74
Registration Number
NCT01575574
Locations
🇪🇸

Hospital Clinic of Barcelona, Barcelona, Spain

Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma

Completed
Conditions
Carcinoma, Hepatocellular
Liver Dysfunction
Interventions
Drug: Gd-EOB-DTPA
Procedure: MRI
First Posted Date
2011-12-12
Last Posted Date
2018-03-23
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
71
Registration Number
NCT01490203
Locations
🇰🇷

Cheonnam University Hwasun Hospital, Hwasun-Gun, Cheonnam Province, Korea, Republic of

🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy